Anti-U3 snRNP antibodies in localised scleroderma
Localised scleroderma (LScl) is a connective tissue disorder usually limited to the skin and subcutaneous tissue, but it sometimes aVects the muscle beneath the cutaneous lesions. The absence of Raynaud's phenomenon, acrosclerosis, and internal organ involvement diVerentiates LScl from systemic sclerosis (SSc).
1 LScl has been reported to be accompanied by a variety of abnormal immune reactions, such as the presence of antinuclear antibody, rheumatoid factor, anti-singlestranded DNA antibody (anti-ssDNA), and antihistone antibody. [2] [3] [4] [5] In our laboratory an indirect immunofluorescent study showed nucleolar staining in the serum samples of some patients with LScl. Although autoantibodies to nucleolar antigens have been well described in patients with SSc, 6 7 these antibodies have not been determined in patients with LScl, and the incidence of anti-U3 snRNP antibodies has not been described previously. In this study we investigated the prevalence of anti-U3 snRNP antibodies using RNA immunoprecipitation, 8 and examined the clinical and laboratory features of patients with LScl. In addition, we examined the serum samples of patients with SSc and control subjects matched for age and sex with the patients with LScl. We found anti-U3 snRNP antibodies in 2/70 (3%) serum samples from the patients with LScl (fig 1) . One of the 28 patients (4%) with linear scleroderma and one of the 20 patients (5%) with morphoea had anti-U3 snRNP antibodies (table 1) . This prevalence was smaller than that in patients with SSc, 9 but there was no significant diVerence. RNA immunoprecipitation using silver staining of the RNA is not as sensitive as other methods-for example, probing with a labelled U3 snRNP probe. Possibly, some anti-U3 snRNP positive serum samples might have been missed. The three patients with SSc and with anti-U3 snRNP antibodies were diagnosed as having diVuse cutaneous SSc, and they tended to be older and have disease of longer duration than patients with LScl; the diVerence was not significant. In this study the titres of antinucleolar antibodies in the two patients with LScl with anti-U3 snRNP antibodies were 1/320 and 1/640, respectively. The titres of this antibody did not change in a follow up study. A previous study reported that 43 Previous studies have shown that anti-U3 snRNP antibodies rarely coexist with other autoantibodies. 9 Okano et al reported that each distinctive serum antibody is associated with its own unique combination of clinical features.
9 In our study antihistone antibodies or anti-ssDNA did not coexist with anti-U3 snRNP antibodies, and no other autoantibodies were detected by RNA immunoprecipitation. LScl may be a heterogeneous condition with diverse autoantibodies, and these antibodies may have a mutually exclusive status.
In conclusion, we showed for the first time that anti-U3 snRNP antibodies are found in patients with LScl by RNA immunoprecipitation. We found no correlations between clinical and laboratory manifestations in the present study. Our study suggests that the presence of anti-U3 snRNP antibodies is one of the serological abnormalities in LScl. A study of more patients may assist in showing a distinctive association between anti-U3 snRNP antibodies and the clinical and laboratory features of patients with LScl. 
Telomerase activity in peripheral blood mononuclear cells from patients with SLE
Telomerase is a reverse transcriptase that adds the telomeric sequence to the terminal of chromosomes, prevents shortening of telomere, and maintains the complete telomeric structure.
1 It has been recently reported that an increase in telomerase activity is associated with the activation of lymphocytes, [2] [3] [4] [5] [6] [7] and, in general, much attention has been paid to the role of telomerase in immunopathology. Katayama et al reported the telomerase activity in patients with systemic lupus erythematosus (SLE).
8 They analysed 17 patients with SLE, and the telomerase activity in peripheral mononuclear cells was increased to 64.7%. Thus, in this study, we divided patients with SLE into treated and untreated groups, and measured the telomerase activity of peripheral mononuclear cells.
Thirteen patients with SLE (1 man, 12 women) with a mean (SD) age of 30.7 (6.5) years (range 19-61) were enrolled in this study. All patients fulfilled the 1997 revised American Rheumatism Association criteria. As a control group, 10 normal volunteers, six women aged 19-41 and four men aged 30-37, were also included in the study. After informed consent had been obtained, 10 ml of peripheral blood was taken and heparinised. The mononuclear cell fraction was isolated from 10 ml of heparinised peripheral blood by Ficoll-Paque (Sigma Inc, St Louis, USA) density gradient centrifugation. A sample of 1.0×10 6 mononuclear cells was analysed by the TRAP assay method. The TRAP assay was performed with a TRAPeze telomerase detection kit produced by the Intergen Company (Purchase, NY, USA). The level of telomerase activity was expressed by a ratio of the entire TRAP ladders to an internal control band. Table 1 shows the telomerase activity level data and clinical data used for determining the SLE Disease Activity Index (SLEDAI). Significant diVerences (p=0.006) were detected in the telomerase activity level between the control group, untreated SLE group, and treated SLE group by Kruskal-Wallis test with a significance level of 5%. For multiple comparisons the Mann-Whitney U test was used to evaluate intergroup diVerences after lowering the significance level using Bonferroni's technique. The p value was 0.002 between the control group and untreated SLE group, 0.005 between the untreated SLE group and treated SLE group, and 0.118 between the control group and treated SLE group. Compared with other groups, telomerase activity was significantly higher in the SLE untreated group. The Spearman rank correlation test with a significance level of 5% showed a significant positive relationship between telomerase activity and SLEDAI in the SLE group with a correlation coeYcient of 0.872 and p value of 0.003. The relation between telomerase activity and clinical data in SLEDAI was also analysed using the Spearman rank correlation test with a significance level of 5% in the SLE group. The correlation coeYcient and p value were −0.614 and 0.033 between telomerase activity and white blood cell count, −0.715 and 0.013 between telomerase activity and serum complement activity, and 0.637 and 0.027 between telomerase activity and serum IgG level, respectively, with a significance level of 5%. However, the relation between telomerase activity and other clinical data was not significant in the SLE group. Telomerase activity was measured before and after treatment and changes in the activity level were analysed.
SLEDAI decreased in all patients after treatment. Wilcoxon signed rank test with a significance level of 5% showed a significant decrease in telomerase activity (p=0.043) after treatment.
The treatment reduced the telomerase activity in peripheral mononuclear cells. We could not confirm whether the cause was due to the steroids or the reduction of disease activity. However, because the telomerase activity of peripheral mononuclear cells was correlated with SLEDAI, the peripheral blood telomerase activity may be useful in the evaluation of disease activity and in judging the therapeutic eVects in SLE. WBC = white blood cell count (/µl); Lymph. = lymphocyte count (/µl); Plt. = platelet count (×10 3 /µl); CH 50 = serum complement activity (U/ml); IC (C1q) = serum immune complex level with a C1q solid phase method (µg/ml),;dsDNA = anti-double stranded DNA antibody level (IU/ml); u-prot. = urine protein analysis with a test paper method; ANA = antinuclear antibody (titre); IgG = immunoglobulin G level (g/l), IgA = immunoglobulin A level (g/l); IgM = immunoglobulin M level (g/l); SLEDAI = SLE disease activity index. Symptom: 1 = central nervous system lupus; 2 = arthritis; 3 = myositis; 4 = nephritis; 5 = new rash; 6 = alopecia; 7 = serositis; 8 = fever.
